Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ9209210,66
KB744745-0,54
PKN63,3463,42-0,82
Msft-2,36
Nokia4,40054,4895-0,35
IBM0,40
Mercedes-Benz Group AG72,0372,06-0,28
PFE-0,63
04.02.2023 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 02.02.2023 10:21:17
Codexis (CDXS.F, Frankfurt)
Závěr k 3.2.2023 Změna (%) Změna (EUR) Objem obchodů (EUR)
5,90 -2,74 -0,17 1 761
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 04.02.2023
Popis společnosti
Obecné informace
Název společnostiCodexis, Inc.
TickerCDXS
Kmenové akcie:Ordinary Shares
RICCDXS.O
ISIN-
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 31.12.2021 261
Akcie v oběhu k 01.11.2022 65 687 012
MěnaUSD
Kontaktní informace
Ulice200 Penobscot Dr
MěstoREDWOOD CITY
PSČ94063-4718
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 504 218 100
Fax13026555049

Business Summary: Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and sells enzymes and other proteins. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The Company has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. It also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The Company is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Codexis, Inc. revenues increased 35% to $108.2M. Net loss increased 89% to $21M. Revenues reflect Performance Enzymes segment increase of 47% to $100.8M, APAC segment increase of 82% to $81.2M. Higher net loss reflects Novel Biotherapeutics segment loss increase from $10.8M to $32.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.17 to -$0.32.
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSAll Other Basic Organic Chemical Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Research and Development in Biotechnology
NAICS2007All Other Basic Organic Chemical Mfg
NAICS2007Medicinal & Botanical Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997All Other Basic Organic Chemical Manufacturing
NAICS1997Medicinal and Botanical Manufacturing
SICCommercial Physical Research
SICIndustrial Organic Chemicals, Nec
SICMedicinals And Botanicals



  • Poslední aktualizace: 04.02.2023
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorStephen Dilly6209.08.202209.08.2022
Chief Financial Officer, Chief Accounting OfficerSriram Ryali4223.01.202323.01.2023
Chief Operating OfficerKevin Norrett4903.10.202203.10.2022
Chief Legal Officer, General CounselMargaret Fitzgerald-01.11.202201.11.2022